Top News
Friday , 20 November 2026
Home Technology Australian biotech investor Brandon Capital hits jackpot as Swiss giant Novartis splashes $2 billion on cancer therapy firm Myrics
Technology

Australian biotech investor Brandon Capital hits jackpot as Swiss giant Novartis splashes $2 billion on cancer therapy firm Myrics

Share


Swiss pharmaceutical giant Novartis has agreed to pay more than $2 billion for early-stage cancer therapy biotech Myricx in a major windfall for the company’s founding investor, Australian venture capital firm Brandon Capital, and its superannuation fund backers.

Novartis said on Monday it would pay $US1.1 billion ($1.6 billion) cash upfront, plus up to $US400 million in milestone payments for London-based Myricx, one of the largest amounts paid for an early-stage pre-clinical biotechnology company.

Loading…



Source link

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles
Technology

University launches new centre for clean energy and environmental innovation

The University of Liverpool has launched a new research centre bringing together...

Technology

UK-EU summit: What another ‘reset’ could mean for carbon, energy and the environment

Brussels is bracing for another attempt to mend the administrative friction of...

Technology

Henderson Technology acquires market-leading htec and Azpiral from PDI Technologies

 Darren Nickels, left, Retail Technology Operations Director at Henderson Technology and Neil...

Technology

The data centre boom: emerging challenges

Answer Reading time: five minutes Summary: What does the data centre boom...